The first single domain antibody being engineered from the heavy-chain antibodies found in camelids has greatly stimulated the development of antibody market.
The Rapid Development of Antibody Drugs
Except brain, the most sophisticated part in a human body is the immune system. In a sense, we are living in a world surrounded by various bacteria. They never cease disturbing us by taking over our living surroundings as their ideal place for breeding. Under this circumstance, antibody is the only one that can take the responsibility of an inner protector. Each antibody model has its own mission. When foreign objects, including microorganism, allergen and toxin, are trying to invade the immune system, antibodies will send out unique chemical signals on receiving which our immune system starts working.
Even with such a complicated self-defense system, we still suffer a lot from disease. While confronting with cancer or respiratory virus infection, the immune system always delays the response. Sometimes it overacts in an asthma attack or when rejection occurs in organ transplantation. It may even mistakenly attack normal cells and leads to rheumatic arthritis and other autoimmune diseases.
For years, pharmaceutical researchers have been trying to create an engineered antibody that can overcome or relieve these immune system diseases. With the efforts of a large group of research team, Creative Biolabs, a US biotech company, successfully engineered single domain antibody which is also called single domain antibody from the heavy-chain antibodies found in camelids. Creative Biolabs owns its success to three factors, the rapid development of therapeutic antibody, the disturbing problems related to antibody drugs and the unique understanding of camelids concerned biological knowledge by its scientists.
Why It Attracts So Much Attention?
Compared with normal antibodies, this distinct antibody, with only 10% of their molecular mass, is more flexible in terms of chemical property. Thanks to its tiny size and non-hydrophobic property, it performs better in heat as well as acidic and alkali resistances. In the experiment on mice, their being able to remain viable and stable while passing through the mice’s digestive system has further proved the possibility of curing diseases by taking antibody drugs.
Based on all these advantages, Creative Biolabs widened its services to meet more requirements from the market, including the construction of immunized antibody libraries of this specialty and synthetic camelised human single domain antibody libraries with the usage of llama and camel and DNA synthesis respectively. Bio-panning of single domain antibodies libraries and large scale production of recombinant single domain antibodies are also the fields of its expansion project.